Discovery of the Clinical Candidate S-892216 : A Second-Generation of SARS-CoV-2 3CL Protease Inhibitor for Treating COVID-19

Related articles

1. Fusion protein pan-sarbecovirus vaccines elicit broadly protective immune responses targeting Clade 1a, 1b, and 3 sarbecoviruses

   This article has 28 authors:

   1. Alyson Kelvin
   2. Matthew Rogers
   3. Zahed Katooni
   4. Eva-Maria Uhlemann
   5. Rachelle Buchanan
   6. Erin Scruten
   7. Anthony Yourkowski
   8. Jocelyne Lew
   9. Akarin Asavajaru
   10. Jill Van Kessel
   11. Paul Pennington
   12. Andrea Kroeker
   13. Cynthia Swan
   14. Rinku Patel
   15. Brittany Thivierge
   16. Willian Deck
   17. Ravendra Garg
   18. Glenn Hamonic
   19. Wolfgang Koster
   20. Tracy Prysliak
   21. Anne-Catherine Fluckiger
   22. Jasminka Bozic
   23. Andrew Van Kessel
   24. Volker Gerdts
   25. Qiang Liu
   26. Arinjay Banerjee
   27. Darryl Falzarano
   28. Trina Racine

2. DIVERSITY AND CLINICAL CORRELATIONS OF SARS-CoV-2 VARIANT DURING THE INTRODUCTION OF THE DELTA VARIANT IN GUATEMALA

   This article has 13 authors:

   1. Claudia Carranza
   2. Lucia Ortiz
   3. Maria Eugenia Castellanos
   4. Ana Silvia Gonzalez-Reiche
   5. Renata Mendizabal-Cabrera
   6. Zain Khalil
   7. Adriana van DeGuchte
   8. Keith Farrugia
   9. Mariana Herrera
   10. Ernesto Mena
   11. Celia Cordon-Rosales
   12. Harm van Bakel
   13. Daniel R. Perez

   Reviewed by Access Microbiology

3. Structural Insights into DENV-2 NS2B-NS3 Protease and Inhibition by Glutathione-Coated Gold Nanocluster

   This article has 14 authors:

   1. Haojia Zhu
   2. Wenchao Niu
   3. Yuancong Xu
   4. Zhaoyang Li
   5. Dongfang Xia
   6. Sixu Chen
   7. Botao Zhang
   8. Junshuai Wang
   9. Huai Yang
   10. Xueyun Gao
   11. Yuanyuan Chen
   12. Yong Gong
   13. Peng Cao
   14. Yubai zhou